ROS1+ lung cancer patients in United Kingdom: we need your help!

To all ROS1+ non-small cell lung cancer (NSCLC) patients in the United Kingdom (UK):

Please help advocate for coverage of crizotinib (Xalkori) for ROS1+ NSCLC through the UK’s national health system.  The Roy Castle Lung Cancer Foundation is putting together a submission on behalf of ROS1+ patients, and they are looking for patient experience quotes, preferably from the UK.  They do not need personal details.

If you are interested in sharing your ROS1+ patient experience, please contact
Nicola Forrest (Support Services Manager for Roy Castle Lung Cancer Foundation) by one of the methods below:

She will get in touch with you after Thursday February 15.

Thanks for your help!

 

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.